Arbutus Biopharma Corp (ABUS) Stock: A Look at the Analyst Recommendations
ABUS has 36-month beta value of 2.05. Analysts have mixed views on the stock, with 4 analysts rating it as a “buy,” 2 as “overweight,”
ABUS has 36-month beta value of 2.05. Analysts have mixed views on the stock, with 4 analysts rating it as a “buy,” 2 as “overweight,”
Arbutus Biopharma Corp (NASDAQ: ABUS) has seen a decline in its stock price by -4.69 in relation to its previous close of 2.88. However, the
Moreover, the 36-month beta value for ABUS is 2.05. The public float for ABUS is 125.20M and currently, short sellers hold a 4.89% of that
The stock of Arbutus Biopharma Corp (ABUS) has seen a 17.00% increase in the past week, with a 25.11% gain in the past month, and
The stock price of Arbutus Biopharma Corp (NASDAQ: ABUS) has jumped by 0.81 compared to previous close of 2.47. Despite this, the company has seen
© 2024, Fueled by Smart TechOne
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.